Summary by Futu AI
Clover Biopharmaceuticals Limited (“Clover Bio-B”) filed with Hong Kong Trading and Clearing Limited on 4 March 2024 an updated Monthly Statement of Changes in Securities Reporting on the Company's share capital as of 29 February 2024. THE REPORT SHOWS THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL AND ISSUED SHARES REMAINED UNCHANGED DURING THE REPORTING PERIOD AT 2,000,000,000 SHARES WITH A FACE VALUE OF $0.0001 PER SHARE FOR A TOTAL AMOUNT OF $200,000. In addition, the Company's share option plan includes a pre-IPO and post-IPO share option plan, in which the Initial Public Offering pre-IPO share option plan was approved by the General Meeting on April 15, 2021, and the Initial Public Possession Option Plan was approved on September 26, 2021. During the reporting period, both plans did not exercise or expire with 2,076,817 shares and 37,346,265 shares outstanding. The Company confirms that all securities issuance has been authorised by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.